{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:33:08Z","timestamp":1781620388612,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Taiwan University Cancer Center","award":["NTUCCS-113-05"],"award-info":[{"award-number":["NTUCCS-113-05"]}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["111-2811-B-002-058"],"award-info":[{"award-number":["111-2811-B-002-058"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","award":["112L901403"],"award-info":[{"award-number":["112L901403"]}],"id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Programmed death-ligand 1 (PD-L1) is a well-recognized predictive biomarker for immunotherapy in non-oncogene-addicted non-small cell lung cancer (NSCLC). However, its role in epidermal growth factor receptor (<jats:italic>EGFR<\/jats:italic>)-mutant NSCLC remains unclear. This study aims to investigate the impact of PD-L1 on the signaling pathways in <jats:italic>EGFR<\/jats:italic>-mutant NSCLC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The regulatory role of PD-L1 was investigated through in vitro manipulation of PD-L1 expression across several EGFR-mutant cell lines, followed by analysis via human receptor tyrosine kinase (RTK) array, Western blotting, protein tyrosine phosphatase (PTPs) activity assays, and mRNA expression profiling. In vivo experiments were carried out using xenograft mice implanted with parental, PD-L1 knock-out and PD-L1 overexpression NCI-H1975 cells. Osimertinib was orally administered to the mice until tumor progression to evaluate the impact of PD-L1 on osimertinib resistance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In human RTK array screening, c-MET phosphorylation was found to be increased in EGFR-mutant PD-L1 overexpressing cells. We found that PD-L1 overexpression upregulated c-MET phosphorylation, while PD-L1 knock-out and knock-down resulted in downregulation of c-MET phosphorylation. Furthermore, we showed that PD-L1 upregulates c-MET phosphorylation by suppressing PTP activity and reducing mRNA expression in selected PTPs. In xenograft mice, <jats:italic>MET<\/jats:italic> amplification only developed in PD-L1 overexpression, but not in PD-L1 knock-out and parental NCI-H1975 cells, at the time of osimertinib resistance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In <jats:italic>EGFR<\/jats:italic>-mutant NSCLC, PD-L1 regulates c-MET phosphorylation and promotes <jats:italic>MET<\/jats:italic> amplification, contributing to osimertinib resistance.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12929-025-01181-3","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T05:00:14Z","timestamp":1759986014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC"],"prefix":"10.1186","volume":"32","author":[{"given":"Chia-Chi","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek De-Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hsun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Shu","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chen","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Yun","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Hui","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yuan","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-Chi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yuan","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Chih-Hsin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"1181_CR1","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa0904554","volume":"361","author":"R Rosell","year":"2009","unstructured":"Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958\u201367.","journal-title":"N Engl J Med"},{"key":"1181_CR2","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947\u201357.","journal-title":"N Engl J Med"},{"key":"1181_CR3","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","volume":"29","author":"WH Hsu","year":"2018","unstructured":"Hsu WH, Yang JC, Mok TS, et al. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018;29:i3\u20139.","journal-title":"Ann Oncol"},{"key":"1181_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113\u201325.","journal-title":"N Engl J Med"},{"key":"1181_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41\u201350.","journal-title":"N Engl J Med"},{"key":"1181_CR6","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/s41556-020-0568-y","volume":"22","author":"A Jaccard","year":"2020","unstructured":"Jaccard A, Ho PC. The hidden side of PD-L1. Nat Cell Biol. 2020;22:1031\u20132.","journal-title":"Nat Cell Biol"},{"key":"1181_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd2712","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N, Wang Q, Strauss L, et al. Revisiting the PD-1 pathway. Sci Adv. 2020. https:\/\/doi.org\/10.1126\/sciadv.abd2712.","journal-title":"Sci Adv"},{"key":"1181_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153\u201367.","journal-title":"Nat Rev Immunol"},{"key":"1181_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41419-020-2701-z","volume":"11","author":"W Yu","year":"2020","unstructured":"Yu W, Hua Y, Qiu H, et al. PD-L1 promotes tumor growth and progression by activating WIP and beta-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death Dis. 2020;11:506.","journal-title":"Cell Death Dis"},{"key":"1181_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12943-019-1073-4","volume":"18","author":"S Peng","year":"2019","unstructured":"Peng S, Wang R, Zhang X, et al. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer. 2019;18:165.","journal-title":"Mol Cancer"},{"key":"1181_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-018-0022-9","volume":"3","author":"D Escors","year":"2018","unstructured":"Escors D, Gato-Canas M, Zuazo M, et al. The intracellular signalosome of PD-L1 in cancer cells. Signal Transduct Target Ther. 2018;3:26.","journal-title":"Signal Transduct Target Ther"},{"key":"1181_CR12","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333.","journal-title":"N Engl J Med"},{"key":"1181_CR13","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819\u201330.","journal-title":"Lancet"},{"key":"1181_CR14","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383:1328\u201339.","journal-title":"N Engl J Med"},{"key":"1181_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01017","author":"T Mok","year":"2024","unstructured":"Mok T, Nakagawa K, Park K, et al. Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.23.01017.","journal-title":"J Clin Oncol"},{"key":"1181_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA900","author":"JC-H Yang","year":"2023","unstructured":"Yang JC-H, Lee DH, Lee J-S, et al. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA900.","journal-title":"J Clin Oncol"},{"key":"1181_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01891","author":"S Park","year":"2023","unstructured":"Park S, Kim TM, Han JY, et al. Phase III, randomized study of Atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19\u201304). J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/JCO.23.01891.","journal-title":"J Clin Oncol"},{"key":"1181_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejca.2019.10.019","volume":"124","author":"CY Yang","year":"2020","unstructured":"Yang CY, Liao WY, Ho CC, et al. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. Eur J Cancer. 2020;124:110\u201322.","journal-title":"Eur J Cancer"},{"key":"1181_CR19","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.jtho.2018.07.016","volume":"13","author":"S Su","year":"2018","unstructured":"Su S, Dong ZY, Xie Z, et al. Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase inhibitors among NSCLC patients with EGFR mutation. J Thorac Oncol. 2018;13:1668\u201375.","journal-title":"J Thorac Oncol"},{"key":"1181_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.lungcan.2018.11.021","volume":"127","author":"KH Hsu","year":"2019","unstructured":"Hsu KH, Huang YH, Tseng JS, et al. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naive advanced EGFR-mutant lung adenocarcinoma patients. Lung Cancer. 2019;127:37\u201343.","journal-title":"Lung Cancer"},{"key":"1181_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jtho.2019.09.009","volume":"15","author":"H Brown","year":"2020","unstructured":"Brown H, Vansteenkiste J, Nakagawa K, et al. Programmed cell death ligand 1 expression in untreated EGFR mutated advanced NSCLC and response to osimertinib versus comparator in FLAURA. J Thorac Oncol. 2020;15:138\u201343.","journal-title":"J Thorac Oncol"},{"key":"1181_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725\u201337.","journal-title":"Br J Cancer"},{"key":"1181_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-2600(17)30480-0","volume":"6","author":"CC Lin","year":"2018","unstructured":"Lin CC, Shih JY, Yu CJ, et al. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. Lancet Respir Med. 2018;6:107\u201316.","journal-title":"Lancet Respir Med"},{"key":"1181_CR24","doi-asserted-by":"publisher","first-page":"S1581","DOI":"10.1016\/j.annonc.2022.10.398","volume":"33","author":"Z Piotrowska","year":"2022","unstructured":"Piotrowska Z, Ahn MJ, Pang YK, et al. 360P elios: a multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib. Ann Oncol. 2022;33:S1581\u20132.","journal-title":"Ann Oncol"},{"key":"1181_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jtho.2019.09.006","volume":"15","author":"CC Hsu","year":"2020","unstructured":"Hsu CC, Liao BC, Liao WY, et al. Exon 16-skipping HER2 as a novel mechanism of osimertinib resistance in EGFR L858R\/T790M-positive non-small cell lung cancer. J Thorac Oncol. 2020;15:50\u201361.","journal-title":"J Thorac Oncol"},{"key":"1181_CR26","doi-asserted-by":"publisher","first-page":"D29","DOI":"10.1093\/nar\/gki098","volume":"33","author":"C Kanz","year":"2005","unstructured":"Kanz C, Aldebert P, Althorpe N, et al. The EMBL nucleotide sequence database. Nucleic Acids Res. 2005;33:D29-33.","journal-title":"Nucleic Acids Res"},{"key":"1181_CR27","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nbt.3080","volume":"33","author":"C Klijn","year":"2015","unstructured":"Klijn C, Durinck S, Stawiski EW, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol. 2015;33:306\u201312.","journal-title":"Nat Biotechnol"},{"key":"1181_CR28","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/nprot.2006.179","volume":"1","author":"V Vichai","year":"2006","unstructured":"Vichai V, Kirtikara K. Sulforhodamine b colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1:1112\u20136.","journal-title":"Nat Protoc"},{"key":"1181_CR29","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrm3012","volume":"11","author":"L Trusolino","year":"2010","unstructured":"Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11:834\u201348.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1181_CR30","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131458","author":"C Chen","year":"2021","unstructured":"Chen C, Li S, Xue J, et al. PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer. JCI Insight. 2021. https:\/\/doi.org\/10.1172\/jci.insight.131458.","journal-title":"JCI Insight"},{"key":"1181_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1021\/acs.accounts.6b00537","volume":"50","author":"ZY Zhang","year":"2017","unstructured":"Zhang ZY. Drugging the undruggable: therapeutic potential of targeting protein tyrosine phosphatases. Acc Chem Res. 2017;50:122\u20139.","journal-title":"Acc Chem Res"},{"key":"1181_CR32","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1126\/science.283.5407.1544","volume":"283","author":"M Elchebly","year":"1999","unstructured":"Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 1999;283:1544\u20138.","journal-title":"Science"},{"key":"1181_CR33","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1128\/MCB.01168-10","volume":"31","author":"JA Kim","year":"2011","unstructured":"Kim JA, Hicks WM, Li J, et al. Protein phosphatases pph3, ptc2, and ptc3 play redundant roles in DNA double-strand break repair by homologous recombination. Mol Cell Biol. 2011;31:507\u201316.","journal-title":"Mol Cell Biol"},{"key":"1181_CR34","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.jtho.2019.07.027","volume":"15","author":"O Gautschi","year":"2020","unstructured":"Gautschi O, Menon R, Bertrand M, et al. Capmatinib and osimertinib combination therapy for EGFR-mutant lung adenocarcinoma. J Thorac Oncol. 2020;15:e13\u20135.","journal-title":"J Thorac Oncol"},{"key":"1181_CR35","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2217\/fon-2021-1406","volume":"18","author":"E Fs","year":"2022","unstructured":"Fs E, Dooms C, Raskin J, et al. INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance. Future Oncol. 2022;18:1039\u201354.","journal-title":"Future Oncol"},{"key":"1181_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","volume":"21","author":"LV Sequist","year":"2020","unstructured":"Sequist LV, Han JY, Ahn MJ, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21:373\u201386.","journal-title":"Lancet Oncol"},{"key":"1181_CR37","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240\u20137.","journal-title":"Clin Cancer Res"},{"key":"1181_CR38","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","volume":"14","author":"J Chmielecki","year":"2023","unstructured":"Chmielecki J, Mok T, Wu YL, et al. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nat Commun. 2023;14:1071.","journal-title":"Nat Commun"},{"key":"1181_CR39","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","volume":"14","author":"J Chmielecki","year":"2023","unstructured":"Chmielecki J, Gray JE, Cheng Y, et al. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nat Commun. 2023;14:1070.","journal-title":"Nat Commun"},{"key":"1181_CR40","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","volume":"6","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6:1118\u201333.","journal-title":"Cancer Discov"},{"key":"1181_CR41","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N Engl J Med. 2021;384:2382\u201393.","journal-title":"N Engl J Med"},{"key":"1181_CR42","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016592","volume":"7","author":"AB Reams","year":"2015","unstructured":"Reams AB, Roth JR. Mechanisms of gene duplication and amplification. Cold Spring Harb Perspect Biol. 2015;7:a016592.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1181_CR43","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.trecan.2020.02.019","volume":"6","author":"H Tanaka","year":"2020","unstructured":"Tanaka H, Watanabe T. Mechanisms underlying recurrent genomic amplification in human cancers. Trends Cancer. 2020;6:462\u201377.","journal-title":"Trends Cancer"},{"key":"1181_CR44","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.cell.2017.01.002","volume":"168","author":"A Tubbs","year":"2017","unstructured":"Tubbs A, Nussenzweig A. Endogenous DNA damage as a source of genomic instability in cancer. Cell. 2017;168:644\u201356.","journal-title":"Cell"},{"key":"1181_CR45","doi-asserted-by":"publisher","first-page":"9888","DOI":"10.1074\/jbc.M110.207290","volume":"286","author":"J Yuan","year":"2011","unstructured":"Yuan J, Chen J. The role of the human SWI5-MEI5 complex in homologous recombination repair. J Biol Chem. 2011;286:9888\u201393.","journal-title":"J Biol Chem"},{"key":"1181_CR46","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.ccell.2023.07.005","volume":"41","author":"FJ de Miguel","year":"2023","unstructured":"de Miguel FJ, Gentile C, Feng WW, et al. Mammalian SWI\/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. Cancer Cell. 2023;41:1516-1534 e1519.","journal-title":"Cancer Cell"},{"key":"1181_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cells11050808","author":"S Thakur","year":"2022","unstructured":"Thakur S, Cahais V, Turkova T, et al. Chromatin remodeler Smarca5 is required for cancer-related processes of primary cell fitness and immortalization. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11050808.","journal-title":"Cells"},{"key":"1181_CR48","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s13046-021-02151-x","volume":"40","author":"Y Li","year":"2021","unstructured":"Li Y, Gong H, Wang P, et al. The emerging role of ISWI chromatin remodeling complexes in cancer. J Exp Clin Cancer Res. 2021;40:346.","journal-title":"J Exp Clin Cancer Res"},{"key":"1181_CR49","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1083\/jcb.200903100","volume":"186","author":"M Amano","year":"2009","unstructured":"Amano M, Suzuki A, Hori T, et al. The CENP-S complex is essential for the stable assembly of outer kinetochore structure. J Cell Biol. 2009;186:173\u201382.","journal-title":"J Cell Biol"},{"key":"1181_CR50","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.molcel.2009.05.016","volume":"34","author":"S Jha","year":"2009","unstructured":"Jha S, Dutta A. RVB1\/RVB2: running rings around molecular biology. Mol Cell. 2009;34:521\u201333.","journal-title":"Mol Cell"},{"key":"1181_CR51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403614","author":"BC Cho","year":"2024","unstructured":"Cho BC, Lu S, Felip E, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2403614.","journal-title":"N Engl J Med"},{"key":"1181_CR52","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nrclinonc.2017.40","volume":"14","author":"CA Bradley","year":"2017","unstructured":"Bradley CA, Salto-Tellez M, Laurent-Puig P, et al. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat Rev Clin Oncol. 2017;14:562\u201376.","journal-title":"Nat Rev Clin Oncol"},{"key":"1181_CR53","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039\u201343.","journal-title":"Science"},{"key":"1181_CR54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/bs.acr.2024.05.002","volume":"162","author":"CL Welsh","year":"2024","unstructured":"Welsh CL, Madan LK. Protein tyrosine phosphatase regulation by reactive oxygen species. Adv Cancer Res. 2024;162:45\u201374.","journal-title":"Adv Cancer Res"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-025-01181-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-025-01181-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-025-01181-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:03:32Z","timestamp":1759989812000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-025-01181-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1181"],"URL":"https:\/\/doi.org\/10.1186\/s12929-025-01181-3","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in accordance with institutional guidelines and were approved by the Institutional Animal Care and Use Committee (IACUC) of National Taiwan University College of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Yang reports personal and\/or institutional fees from Amgen, grants and personal and institutional fees from AstraZeneca, institutional fees from Bayer, personal and institutional fees from Boehringer Ingelheim, personal fees from Bristol Myers Squibb, institutional fees from Daiichi Sankyo, institutional fees from Eli Lilly, institutional fees from Merck KGaA, Darmstadt, Germany, institutional fees from Merck Sharp & Dohme, personal and institutional fees from Novartis, personal fees from Ono Pharmaceuticals, personal fees from Pfizer, personal and institutional fees from Roche\/Genentech, personal and institutional fees from Takeda Oncology, personal and institutional fees from Yuhan Pharmaceuticals, institutional fee from JNJ, outside the submitted work. No potential conflicts of interest were disclosed by the other authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}